Five companies that could buy Ariad this year for as much as $2.9B

At this point there is little doubt that Ariad is seeking to sell itself. Here are five companies that could be interested.

​Q&A with rare disease mom and biotech CEO Karen Aiach

Aiach, 44, is now the CEO of the French biotech Lysogene, which has raised $30 million to date and completed an early-stage trial of a treatment which replaces the gene that’s defective in Sanfilippo patients.

What’s so ‘groundbreaking’ about Curis’ new cancer drug that just began human trials?

The trial of CA-170, which dosed its first patient last week, represents the first study of an immuno-oncology pill rather than an IV.

​Foreign subsidiary of Analogic to pay $14M to settle bribery charges

According to U.S. Attorney Carmen M. Ortiz, Denmark-based BK Medical ApS, falsified records to hide payments to people unconnected with the sale of ultrasound equipment.

Radius Health opens Philadelphia facility with plans to hire 100-plus

Boston Business Journal Science & Tech Newsletters